Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Bradenton, Florida Clinical Trials

A listing of Bradenton, Florida clinical trials actively recruiting patient volunteers.

Found (32) clinical trials

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in participants with selected, advanced or recurrent solid tumors with the aim …

Phase

5.43 miles

Learn More »

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

The study will be conducted in two segments. The first segment of the study, designated Phase 1a, will be a dose escalation design in order to assess the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of ascending doses of AZD4635 as monotherapy, in combination with durvalumab or durvalumab plus …

Phase

5.43 miles

Learn More »

Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

This is a first in human, multinational, phase 1, open-label study of TAS3681 in patients with metastatic castration resistant prostate cancer (mCRPC)evaluating safety, tolerability, pharmacokinetics and preliminary antitumor activity in patients with mCRPC for which there is no standard therapy. Eligible patients will either be enrolled in the dose escalation …

Phase

5.43 miles

Learn More »

RBN-2397 an Oral PARP7 Inhibitor in Patients With Solid Tumors FIH MAD Study

This is a first-in-human, Phase 1, multi-center, open-label, dose-escalation study to: Evaluate the safety profile and MTD of RBN-2397 administered orally and establish the RBN-2397 dose(s) and schedule(s) recommended for further investigation in Phase 2 Characterize the PK profile of RBN-2397 Identify preliminary antitumor activity. Biomarkers and their correlation with …

Phase

5.43 miles

Learn More »

A Study of CC-99712 a BCMA Antibody-Drug Conjugate in Subjects With Relapsed and Refractory Multiple Myeloma

Study CC-99712-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical study of CC-99712 in subjects with relapsed and refractory multiple myeloma (MM). The dose escalation part (Part A) of the study will evaluate the safety and tolerability of escalating doses of CC-99712, …

Phase

5.43 miles

Learn More »

Study of AZD9833 Alone or in Combination With Palbociclib in Women With Advanced Breast Cancer

This is a first-in-human study of AZD9833 monotherapy (Parts A and B) and AZD9833 in combination with palbociclib (Parts C and D) in women with ER Positive HER2 Negative advanced breast cancer that is not amenable to treatment with curative intent. Parts A and C of the study allow for …

Phase

5.43 miles

Learn More »

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients With Advanced Malignancies

This is a Phase 1, open-label, multicenter, dose escalation study of intratumoral injections of mRNA-2752 alone and in combination with intravenously administered immune checkpoint blockade therapy in patients with histologically confirmed advanced or metastatic solid tumor malignancies or lymphoma. The study consists of 2 dose escalation and dose confirmation parts …

Phase

5.43 miles

Learn More »

Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

This study will evaluate the safety and tolerability of PMD-026 using an accelerated titration design to define the MTD in metastatic breast cancer, followed by an expansion at the RP2D in triple negative breast cancer. All patients will receive daily oral doses of PMD-026 until either disease progression or unacceptable …

Phase

5.43 miles

Learn More »

RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors

Dose escalation/dose expansion study to assess the MTD, safety, tolerability, PK and preliminary anti-tumor activity of RLY-1971. Approximately 50 patients.

Phase

5.43 miles

Learn More »

A Study of JNJ-64619178 an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors NHL and Lower Risk MDS

The study is designed to determine the maximum tolerated dose (MTD) of JNJ-64619178, and to select a dose(s) and regimen(s) that may be used in future clinical development. Study evaluations will include safety, pharmacokinetics, biomarkers and efficacy evaluations (Disease Assessments). Adverse events will be evaluated throughout the study. The study …

Phase

5.43 miles

Learn More »